HDAC-IN-79

• Description :

  HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM; ), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition[1].

• UNSPSC :

  12352211

• Target :

  Apoptosis; Autophagy; HDAC; Xanthine Oxidase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

• Field of Research :

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/hdac-in-79.html

• Smiles :

  CC(C)COC1=CC=C(C2=NC(C)=C(C(NCCCCCCC(NO)=O)=O)S2)C=C1C#N

• Molecular Formula :

  C23H30N4O4S

• Molecular Weight :

  458.57

• References & Citations :

  [1]Liao Z Y, et al. Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity[J]. European journal of medicinal chemistry, 279: 116866.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC6